Trial Profile
Resource Utilisation and Patient Satisfaction With SWitching INsulin (SWING).
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2009
Price :
$35
*
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SWING
- Sponsors Eli Lilly and Company
- 17 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 07 Nov 2007 New trial record.